Last reviewed · How we verify
177Lu-DOTATATE
177Lu-DOTATATE is a radioligand therapy that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation to kill them.
177Lu-DOTATATE is a radioligand therapy that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation to kill them. Used for Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Somatostatin receptor-positive midgut neuroendocrine tumors.
At a glance
| Generic name | 177Lu-DOTATATE |
|---|---|
| Also known as | 177Lu-octreotate, Lutate, Lutathera®, ¹⁷⁷Lu-DOTA0-TATE, Lu oxodotreotide |
| Sponsor | Erasmus Medical Center |
| Drug class | Radioligand therapy |
| Target | Somatostatin receptor 2 (SSTR2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
177Lu-DOTATATE consists of lutetium-177, a beta-emitting radioisotope, conjugated to DOTATATE, a somatostatin receptor 2 (SSTR2) targeting peptide. The peptide binds with high affinity to SSTR2 expressed on neuroendocrine tumor cells, allowing the radioactive lutetium to deliver cytotoxic radiation directly to tumor tissue while minimizing systemic exposure.
Approved indications
- Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Somatostatin receptor-positive midgut neuroendocrine tumors
Common side effects
- Nausea
- Vomiting
- Fatigue
- Bone marrow suppression
- Kidney toxicity
Key clinical trials
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Targeted Therapy and Avelumab in Merkel Cell Carcinoma (PHASE1, PHASE2)
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (PHASE2)
- Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (PHASE1)
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (PHASE2)
- Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors (PHASE2)
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |